Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has completed enrollment in APPROACH, its Phase 3 pivotal study evaluating HLP003 for major depressive disorder. The company anticipates topline data in the fourth quarter of 2026, a key milestone that could bring a new treatment option to patients with this debilitating condition.
The APPROACH study is part of the PARADIGM program, which also includes the EMBRACE trial, where enrollment is currently underway. Additionally, participants from earlier trials are rolling over into the EXTEND study, designed to gather long-term safety and efficacy data. The company is also advancing HLP004 for generalized anxiety disorder, following Phase 2 results that showed statistically significant and clinically meaningful improvement from baseline. A next study design for HLP004 is expected to be completed by the end of the third quarter of 2026.
Financially, Helus Pharma reported cash of $166.4 million as of June 30, 2026, and a quarterly net loss of $47.8 million, compared with $24.6 million in the same period last year. Cash-based operating expenses increased to $37.5 million from $23.9 million a year earlier, driven by the continued advancement of the Phase 3 trials. The company also continues to progress HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027.
Helus Pharma, the commercial operating name of Cybin Inc., is focused on developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. These investigational therapies aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder, underscoring its potential to offer durable improvements in mental health.
The completion of enrollment in the APPROACH trial is a critical step toward potentially bringing HLP003 to market. If successful, HLP003 could provide a new option for the millions of patients who do not adequately respond to existing antidepressants. The company's progress in Phase 3 development also reflects the growing interest in psychedelic-inspired treatments for mental health disorders, an area that has seen increased investment and research in recent years.
Investors and stakeholders are watching closely as Helus Pharma moves toward data readouts that could shape the future of depression treatment. The company's robust pipeline and financial position provide a foundation for continued advancement, with multiple programs targeting significant unmet needs in mental health.
